Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

Similar articles for PubMed (Select 11377509)

1.

Immunosuppression in ANCA-associated vasculitis.

van der Woude FJ, Schmitt WH, Birck R, Nowack R, Göbel U, Drexler JM, Hotta O.

Transplant Proc. 2001 May;33(3):2225-6. No abstract available.

PMID:
11377509
2.

Plasma exchange for induction and cyclosporine A for maintenance of remission in Wegener's granulomatosis--a clinical randomized controlled trial.

Szpirt WM, Heaf JG, Petersen J.

Nephrol Dial Transplant. 2011 Jan;26(1):206-13. doi: 10.1093/ndt/gfq360. Epub 2010 Jun 24.

3.

A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis.

Joy MS, Hogan SL, Jennette JC, Falk RJ, Nachman PH.

Nephrol Dial Transplant. 2005 Dec;20(12):2725-32. Epub 2005 Sep 27.

4.

15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy.

Birck R, Warnatz K, Lorenz HM, Choi M, Haubitz M, Grünke M, Peter HH, Kalden JR, Göbel U, Drexler JM, Hotta O, Nowack R, Van Der Woude FJ.

J Am Soc Nephrol. 2003 Feb;14(2):440-7.

5.

Azathioprine or methotrexate maintenance for ANCA-associated vasculitis.

Gelber AC.

N Engl J Med. 2009 Mar 26;360(13):1358-9; author reply 1359. No abstract available.

PMID:
19330939
6.

[ANCA-associated vasculitis. New concepts and strategies in therapy].

de Groot K, Haubitz M, Haller H.

Internist (Berl). 2000 Oct;41(10):1112-9. Review. German. No abstract available.

PMID:
11084898
7.

Rituximab therapy for Wegener's granulomatosis refractory to conventional treatment.

Sánchez-Escuredo A, Núñez R, Ibernón M, Martínez E, López D, Navarro M, Bonet J, Ara J, Romero R.

Nefrologia. 2011;31(4):502-4. doi: 10.3265/Nefrologia.pre2011.May.10772. English, Spanish. No abstract available.

8.

Mycophenolate mofetil eliminates the rationale for antilymphocyte induction therapy in nonhaploidentical living-donor kidney transplants.

Shaffer D, Madras PN, Conway P, Davis C, Simpson MA, Monaco AP.

Transplant Proc. 1997 Feb-Mar;29(1-2):342-3. No abstract available.

PMID:
9123031
9.

Azathioprine or methotrexate maintenance for ANCA-associated vasculitis.

Jourde N, Mancini J, Chiche L.

N Engl J Med. 2009 Mar 26;360(13):1358; author reply 1359. doi: 10.1056/NEJMc090138. No abstract available.

10.

Could steroids be withdrawn in renal transplant patients sequentially treated with ATG, cyclosporine, and cellcept? One-year results of a double-blind, randomized, multicenter study comparing normal dose versus low-dose and withdrawal of steroids. M 55002 French Study Group.

Lebranchu Y, Aubert P, Bayle F, Bedrossian J, Berthoux F, Bourbigot B, Buchler M, Chalopin JM, Deteix P, Glotz D, Huraut De Ligny B, Kessler M, Lang P, Lefrancois N, Le Pogamp P, Moulin B, Mourad G, Olmer M, Sraer JD, Touchard G, Toupance O, Wolf P, Puget S.

Transplant Proc. 2000 Mar;32(2):396-7. No abstract available.

PMID:
10715452
11.

Abbreviated cyclosporine pharmacokinetic profiling in clinical renal transplantation: from principles to practice.

Vathsala A, Lu YM.

Transplant Proc. 2001 Nov-Dec;33(7-8):3137-9. No abstract available.

PMID:
11750348
12.

[Vasculitis management: discovery of antineutrophil cytoplasmic antibodies (ANCA)].

Guillevin L.

Presse Med. 2007 May;36(5 Pt 2):843-4. French. No abstract available.

13.

Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation.

Booth AD, Jayne DR, Kharbanda RK, McEniery CM, Mackenzie IS, Brown J, Wilkinson IB.

Circulation. 2004 Apr 13;109(14):1718-23. Epub 2004 Mar 22.

14.

ANCA-associated vasculitis with renal involvement: an outcome analysis.

Weidner S, Geuss S, Hafezi-Rachti S, Wonka A, Rupprecht HD.

Nephrol Dial Transplant. 2004 Jun;19(6):1403-11. Epub 2004 Apr 6.

15.

Anti-T-cell-antibody prophylaxis in children: success with a novel combination strategy of mycophenolate mofetil and antithymocyte serum.

Boucek MM, Pietra B, Sondheimer H, Luna M, Shaffer E, Hall P, Campbell D.

Transplant Proc. 1997 Dec;29(8A):16S-20S. No abstract available.

PMID:
9414669
16.
17.

Living unrelated kidney donation: an underutilized resource?

Ploeg RJ, Pirsch JD, Stegall MD, Armbrust MJ, Lorentzen DF, D'Alessandro AM, Knechtle SJ, Sollinger HW, Kalayoglu M, Belzer FO.

Transplant Proc. 1993 Feb;25(1 Pt 2):1532-4. No abstract available.

PMID:
8442177
18.

Novel therapies for anti-neutrophil cytoplasmic antibody-associated vasculitis.

Tervaert JW, Stegeman CA, Kallenberg CG.

Curr Opin Nephrol Hypertens. 2001 Mar;10(2):211-7. Review.

PMID:
11224696
19.

Enhanced response to basiliximab in a patient with aplastic anemia after treatment with standard immunosuppression.

Berman JA, Patel K, Caro J.

Am J Hematol. 2002 Sep;71(1):64. No abstract available.

PMID:
12221685
20.

Evaluation of various immunosuppressive regimes in second renal transplants.

Toronyi E, Remport A, Járay J, Máthé Z, Borka P, Perner F.

Transplant Proc. 2001 May;33(3):2315-6. No abstract available.

PMID:
11377543
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk